This will be a randomized controlled pilot trial comparing usual care to a precision approach to dialysis potassium prescribing. The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).
Undergoing in-center, 3x/weekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days
Age at least 21 years
Prescribed HD time up to 15 hours/ week
Incarcerated
Life expectancy of 1 year or less
Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less
Cognitive condition that precludes consent
NYU Langone Health
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator